The short answer
It is uncertain how much, if at all, mixed EPA/DHA fish oil adds to bleeding risk with celecoxib. Celecoxib itself can cause gastrointestinal bleeding. Prescription purified EPA has a separate bleeding warning, which should not be applied automatically to every omega-3 supplement.
What this answer covers
This answer concerns oral celecoxib. It distinguishes mixed EPA/DHA fish oil from prescription icosapent ethyl and keeps the original studies' populations and formulations separate. Evidence does not automatically extend to ALA, DPA, krill, algal or multi-ingredient products.
- Supplement or preparation
- omega-3
- Medication ingredient
- celecoxib
What does the research show?
A 2024 analysis of 11 randomized trials involving 120,643 participants found no statistically significant overall increase in bleeding with omega-3 treatment (rate ratio 1.09; 95% confidence interval 0.91 to 1.31). Its high-dose purified EPA subgroup had an absolute increase of 0.6 percentage points. These results do not provide a celecoxib-specific risk estimate. The VASCEPA label reports bleeding in 12% of treated patients versus 10% with placebo, and serious bleeding in 3% versus 2%. These figures concern prescription icosapent ethyl in its cardiovascular outcomes trial, not ordinary fish oil taken with celecoxib.
Have the products been studied together?
A 2007 trial assigned 22 people with advanced lung cancer to fish oil with celecoxib or fish oil with placebo. Its accessible abstract describes inflammatory and nutritional outcomes but supplies no comparative bleeding results. Full text was not available for this assessment. A 2020 feasibility trial enrolled 20 people with advanced lung cancer and cachexia. Both groups received EPA and celecoxib; one also received exercise and amino acids. It cannot show whether adding omega-3 to celecoxib changes bleeding risk, and most participants did not complete 20 weeks.
Why do the exact products matter?
A short trial in healthy adults found that celecoxib did not reduce platelet aggregation or prolong bleeding time in the way naproxen did. That laboratory finding does not remove celecoxib's gastrointestinal risks or establish safety with omega-3. A shared omega-3 label does not make different preparations equivalent. A source may inform a formulation-specific warning without proving the broader supplement–medication claim.
What should I discuss with my pharmacist?
Review your exact product, dose, other medicines, and any previous ulcers or bleeding. Celecoxib's labeling identifies higher gastrointestinal risk with factors such as older age, anticoagulants, aspirin and oral corticosteroids. This assessment found no evidence-supported spacing interval or universal safe dose for the combination.
Evidence and practical considerations
Side effects & toxicity
The retrieved direct co-use studies do not estimate the incremental bleeding effect of omega-3 added to celecoxib. Broader omega-3 bleeding trials and the purified EPA warning cannot establish that exact broad-pair effect. The proposed conclusion is uncertainty, not refutation or proof of safety.
- Exact scope
- omega-3 preparations, distinguishing mixed EPA/DHA fish oil from prescription purified EPA with oral celecoxib
- Medication form and route
- oral celecoxib capsules
- Timing or duration
- The small co-use studies lasted six or twenty weeks; neither provides a comparative estimate of bleeding risk from adding omega-3 to celecoxib.
What remains uncertain
- No retrieved study estimates bleeding risk for omega-3 added to celecoxib versus celecoxib alone.
- Broad omega-3 and prescription EPA evidence is indirect for this exact pair.
- The two direct co-use studies concern small, medically complex cancer populations.
- Source S4 was assessed at abstract level; S2's full text could not be freshly fetched.
Factors that may matter: previous ulcers or gastrointestinal bleeding; older age; concomitant anticoagulants, aspirin or oral corticosteroids.
Read the supporting source summaries
Source 1: regulatory product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral celecoxib capsules.
Defines gastrointestinal bleeding warnings and factors that increase risk.
How this applies: Medication baseline risk and discussion points only.
Does not name omega-3 or quantify this pair.
Source 2: systematic review meta analysis
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 120,643 trial participants across 11 randomized studies; databases searched through May 2023.
Overall bleeding result nonsignificant; purified EPA subgroup showed a small absolute increase.
How this applies: Indirect bleeding context, retaining the purified EPA distinction.
Study-level analysis; no celecoxib-specific estimate. Fresh full-text requests failed.
Source 3: regulatory product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: 8,179 statin-treated cardiovascular outcomes trial participants.
Bleeding warning; concomitant antithrombotic therapy associated with higher incidence.
How this applies: Explains why purified EPA evidence must be separated from general fish oil.
No celecoxib-specific estimate; applies to this prescription preparation.
Source 4: randomized human trial
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Randomized cohort of 22 patients with advanced lung cancer and systemic immune-metabolic syndrome.
Direct co-use was studied for cachexia-related outcomes.
How this applies: Documents coadministration, not incremental omega-3 bleeding risk.
Abstract provides no bleeding comparison; full text inaccessible; no celecoxib-only arm.
Source 5: randomized feasibility trial
onlinelibrary.wiley.com · Source check Sep 10, 2026
Population: 20 patients with late-stage NSCLC and refractory cachexia; open-label feasibility study.
Evaluated acceptability and cachexia outcomes.
How this applies: Direct co-use evidence only. Do not equate the study's EPA with prescription icosapent ethyl.
No group without the combination; 70% attrition at 20 weeks; no comparative bleeding endpoint reported.
Source 6: randomized pharmacodynamic trial
accp1.onlinelibrary.wiley.com · Source check Sep 10, 2026
Population: 24 healthy adults; randomized double-blind ten-day study.
Celecoxib did not show naproxen's platelet aggregation and bleeding-time effects.
How this applies: Prevents unsupported transfer of nonselective NSAID platelet effects to celecoxib.
No omega-3; surrogate outcomes; supratherapeutic exposure; not a clinical bleeding-risk estimate.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Primary sources checked, formulation limits documented and checker statement reassessed. | |
| Research summary published |
Article revision: a63898d8e1dbd835
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.